Incidence, Risk Factors, and Outcomes of Sclerosis in Patients with Chronic Graft-versus-host Disease

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2013 Apr 3

PMID 23547053

Citations 50

Authors

Yoshihiro Inamoto

Barry E Storer

Effie W Petersdorf

J Lee Nelson

Stephanie J Lee

Paul A Carpenter

Brenda M Sandmaier

John A Hansen

Paul J Martin

Mary E D Flowers

Affiliations

Soon will be listed here.

Abstract

Sclerotic chronic graft-versus-host disease (GVHD) can result in disability after allogeneic hematopoietic cell transplantation. We assessed the incidence and risk factors of sclerosis and its association with transplant outcomes among 977 consecutive patients treated with systemic immunosuppression for chronic GVHD. Sclerosis was defined when cutaneous sclerosis, fasciitis, or joint contracture was first documented in the medical record. Seventy (7%) patients presented with sclerosis at the time of initial systemic treatment for chronic GVHD, and the cumulative incidence of sclerosis increased to 20% at 3 years. Factors associated with an increased risk of sclerosis included the use of a mobilized blood cell graft and a conditioning regimen with > 450 cGy total body irradiation. Factors associated with a decreased risk of sclerosis included the use of an HLA-mismatched donor and a major ABO-mismatched donor. Development of sclerosis was associated with longer time to withdrawal of immunosuppressive treatment but not with risks of overall mortality, nonrelapse mortality, or recurrent malignancy. We found a substantial incidence of sclerosis in patients with chronic GVHD. Development of sclerosis can cause disability but does not affect mortality or recurrent malignancy in patients with chronic GVHD.

Citing Articles

Elephantiasis nostra verrucosa in sclerodermatous chronic graft-versus-host disease.

Mammadova J, Glass L, LaFave D, Pidala J, Lazaryan A JAAD Case Rep. 2025; 57:22-24.

PMID: 39936157 PMC: 11810717. DOI: 10.1016/j.jdcr.2024.11.040.

Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease.

Miyao K, Murata M, Nishida T, Ozawa Y, Uchida N, Fukuda T Int J Hematol. 2024; 121(1):110-125.

PMID: 39543007 DOI: 10.1007/s12185-024-03871-4.

Patient experience: Feeling like the tin man from the Wizard of Oz.

Dalton C, Murphy L, Galligan C, OGorman S, Bacon L, Howard-James C Skin Health Dis. 2024; 4(5):e406.

PMID: 39355747 PMC: 11442048. DOI: 10.1002/ski2.406.

A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.

Bhatt V, Shostrom V, Choe H, Hamilton B, Gundabolu K, Maness L J Clin Oncol. 2024; 42(33):3977-3985.

PMID: 39151112 PMC: 11568950. DOI: 10.1200/JCO.24.00205.

Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease.

Strobl J, Gail L, Krecu L, Madad S, Kleissl L, Unterluggauer L Br J Dermatol. 2023; 190(3):402-414.

PMID: 38010706 PMC: 10873647. DOI: 10.1093/bjd/ljad402.

References

Janin A, Socie G, Devergie A, Aractingi S, Esperou H, Verola O . Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases. Ann Intern Med. 1994; 120(12):993-8. DOI: 10.7326/0003-4819-120-12-199406150-00004. View

Gooley T, Leisenring W, Crowley J, Storer B . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18(6):695-706. DOI: 10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o. View

Shulman H, Kleiner D, Lee S, Morton T, Pavletic S, Farmer E . Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006; 12(1):31-47. DOI: 10.1016/j.bbmt.2005.10.023. View

Storb R, Prentice R, Sullivan K, Shulman H, Deeg H, Doney K . Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983; 98(4):461-6. DOI: 10.7326/0003-4819-98-4-461. View

Arora M, Klein J, Weisdorf D, Hassebroek A, Flowers M, Cutler C . Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011; 117(24):6714-20. PMC: 3123030. DOI: 10.1182/blood-2010-12-323824. View

Inamoto Y, Flowers M, Lee S, Carpenter P, Warren E, Deeg H . Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood. 2011; 118(2):456-63. PMC: 3138695. DOI: 10.1182/blood-2011-01-330217. View

Rocha V, Crotta A, Ruggeri A, Purtill D, Boudjedir K, Herr A . Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseases. Best Pract Res Clin Haematol. 2010; 23(2):223-9. DOI: 10.1016/j.beha.2010.07.005. View

Gabrielli A, Avvedimento E, Krieg T . Scleroderma. N Engl J Med. 2009; 360(19):1989-2003. DOI: 10.1056/NEJMra0806188. View

Skert C, Patriarca F, Sperotto A, Cerno M, Fili C, Zaja F . Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica. 2006; 91(2):258-61. View

10.

Biedermann B, Sahner S, Gregor M, Tsakiris D, Jeanneret C, Pober J . Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet. 2002; 359(9323):2078-83. DOI: 10.1016/S0140-6736(02)08907-9. View

11.

Vigorito A, Campregher P, Storer B, Carpenter P, Moravec C, Kiem H . Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009; 114(3):702-8. PMC: 2713471. DOI: 10.1182/blood-2009-03-208983. View

12.

Zhang Y, McCormick L, Desai S, Wu C, Gilliam A . Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002; 168(6):3088-98. DOI: 10.4049/jimmunol.168.6.3088. View

13.

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

14.

Hill G, Olver S, Kuns R, Varelias A, Raffelt N, Don A . Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood. 2010; 116(5):819-28. DOI: 10.1182/blood-2009-11-256495. View

15.

Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin J . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001; 19(16):3685-91. DOI: 10.1200/JCO.2001.19.16.3685. View

16.

Flowers M, Inamoto Y, Carpenter P, Lee S, Kiem H, Petersdorf E . Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011; 117(11):3214-9. PMC: 3062319. DOI: 10.1182/blood-2010-08-302109. View

17.

Amir A, van der Steen D, Hagedoorn R, Kester M, van Bergen C, Drijfhout J . Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. Blood. 2011; 118(26):6733-42. DOI: 10.1182/blood-2011-05-354787. View

18.

Lee S, Vogelsang G, Flowers M . Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003; 9(4):215-33. DOI: 10.1053/bbmt.2003.50026. View

19.

Atkinson K, Horowitz M, Gale R, van Bekkum D, Gluckman E, GOOD R . Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990; 75(12):2459-64. View

20.

Gratwohl A, Gratwhol A, Moutsopoulos H, Chused T, Akizuki M, WOLF R . Sjögren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med. 1977; 87(6):703-6. DOI: 10.7326/0003-4819-87-6-703. View